María José
García Sánchez
Catedrática de Universidad
Hospital Universitario de Salamanca
Salamanca, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario de Salamanca (45)
2024
-
Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 18, Núm. 1, pp. 65-74
2023
-
Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry
Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91
-
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety
American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247
2022
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients
Pharmaceutics, Vol. 14, Núm. 4
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
2020
-
Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy
European Journal of Pharmaceutical Sciences, Vol. 153
2019
-
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study
Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500
2017
-
P567Early diagnosis of anthracycline induced cardiotoxicity in a swine model by serial multiparametric cardiac magnetic resonance
European Heart Journal, Vol. 38, Núm. suppl_1
2016
-
Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma
British Journal of Clinical Pharmacology, Vol. 82, Núm. 6, pp. 1517-1527
2014
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
-
Validation and clinical evaluation of a UHPLC method with fluorescence detector for plasma quantification of doxorubicin and doxorubicinol in haematological patients
Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 955-956, Núm. 1, pp. 93-97
2013
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2011
-
Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients
Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582
2010
-
Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer
Breast Cancer Research and Treatment, Vol. 123, Núm. 1, pp. 149-157
-
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585
2009
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798
-
Vancomycin dosage optimization in patients with malignant haematological disease by pharmacokineticpharmacodynamic analysis
Clinical Pharmacokinetics, Vol. 48, Núm. 4, pp. 273-280